4D Molecular Therapeutics (FDMT) revenue breakdown
By region, Japan is the largest at 100% of fiscal 2025 revenue.
Revenue by region
Fiscal years, as 4D Molecular Therapeutics reports them in its 10-K filings; fiscal 2025 total $85M.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Japan | — | — | — | — | — | $85M | 100% |
| United States | $666,000 | -$27,000 | $121,000 | $35,000 | $20M | $209,000 | 0% |
| Switzerland | $6M | $13M | $17M | — | — | — | — |
| Netherlands | $26,000 | $742,000 | $736,000 | $3M | $567,000 | — | — |
| Australia | $7,000 | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FDMT.
Open FDMT in InvestinglyQuestions
Where does 4D Molecular Therapeutics make its money?
In fiscal 2025, by region: Japan $85M, United States $209,000.
From 4D Molecular Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.